

Drug	Indication	Decision	Notes
Vibro-Pulse	Venous leg ulcers, lower limb oedema, cellulitis etc.	RED-RED	A vibrating plate used with prescribed covers (changed three times a day at a daily cost of £15) to deliver cycloidal vibration. Paucity of evidence and poorly controlled trials make it difficult to determine the additional effects of the treatment over compression and bed-rest.
<i>Relvar Ellipta</i> (vilanterol / fluticasone furoate)	COPD (FEV1<70% & exacerbations) Asthma (12+)	RED-RED	Once daily combination LABA & steroid dry powder inhaler. 22 mcg / 92mcg inhaler is £27.80 (30 doses) licensed for COPD & asthma with 22mcg / 184mcg licensed for asthma (£38.87). Lower cost than other combination inhalers but currently insufficient evidence of comparative efficacy compared to Seretide & Symbicort. Local specialist opinion is that on current evidence its only advantage is once daily administration. Six week expiry in use (moisture sensitive), dose counter & easy to use device. Blue inhaler so conflicts with the blue inhaler is a 'reliever' message.
Coban 2 & Coban 2 Lite	Compression bandage	RED	Added to formulary for lymphoedema service only - requires less frequent changing than other formulary product (Actico Cohesive short stretch compression bandage)
Avanafil 50mg, 100mg & 200mg tabs (<i>Spedra</i>)	Erectile dysfunction	RED-RED	New PDE-5 inhibitor for ED. No comparative data with other agents.
<i>Upostelle</i> (levonorgestrel 1.5mg) tablets	EHC	GREEN	A lower cost brand of levonorgestrel 1.5mg at £4.42 vs. £5.20 for Levonelle / levonorgestrel
Resource ThickenUp Clear	Swallowing difficulties	AMBER	Xanthan gum based thickening agent. Advantages over starch based products (1) transparent & flavourless (2)does not thicken further over time (3) is not degraded by amylase in saliva if held in mouth. Food & drink thickeners should only be prescribed following a SALT assessment.

In response to the recent shortage of naftidrofuryl 100mg capsules, some secondary care specialists are advising that patients should be temporarily moved to **cilostazol** until supplies can be restored. As treatment options for these patients are extremely limited, and subject to individual patient review, PACEF are in support of this advice. Cilostazol 100mg tabs are temporarily designated GREEN.

Domperidone - Following a European cardiovascular safety review the marketing authorisation will change. (1) Contraindications extended (2) Maximum doses are reduced (e.g. adult dose reduced to a max.30mg daily) (3) duration of treatment should not usually exceed 1 week (4) Licence is restricted to management of nausea & vomiting (dyspepsia & GORD will no longer be licensed indications). Review of patients is recommended but limited alternative licensed options (metoclopramide is now limited to up to 5 days treatment, maximum adult dose 30mg because of risk of neurological effects). Record informed patient consent for unlicensed use. Both metoclopramide & domperidone have been designated AMBER for new patients.